Company Research Report: Curebase

Company Overview

• Name: Curebase

• Mission: Curebase aims to seamlessly integrate innovative technology into a user-friendly eClinical platform, enhancing the experience of conducting and participating in clinical research.

• Founded: 2017

• Founder(s): No information is available.

• Key People:

• Tom Lemberg, CEO

• Storm Stillman, COO

• Scott Garcia, CFO

• Headquarters: San Francisco, CA

• Number of Employees: 51-200 employees

• Revenue: No information is available.

• Known For: Curebase is known for its innovative approach to clinical trials, focusing on a modern participant experience through the use of ePRO/eCOA, eConsent, and EDC technologies.

Products

1. ePRO/eCOA

• Description: This product offers a powerful endpoint collection with rapid configurability, providing a leading patient experience in the industry.

• Key Features:

• Enhanced configurability for study needs.

• Engaging patient experience with targeted notifications to minimize drop-offs.

2. eConsent

• Description: A convenient, paperless consent experience that supports multimedia educational content, multiple languages, countries, and complex workflows.

• Key Features:

• Fully remote and site-based consent capabilities.

• Multi-language support with site-level customization options.

3. Unified Participant Experience

• Description: This allows patients to move from prescreening through to a patient portal and data submission in a single mobile experience.

• Key Features:

• Seamless experience across stages of participation.

4. EDC (Electronic Data Capture)

• Description: A unified data platform for hybrid and site-based studies, offering robust data collection with monitoring and management capabilities.

• Key Features:

• User-centric data collection with powerful reporting tools.

• Supports scalability for large studies.

Recent Developments

• $40M Series B Funding (June 2022): Curebase secured $40 million in funding to expand its business and emphasize decentralized clinical trials. This round attracted significant backers, including Gilead.

• New Partnerships: No specific new partnerships mentioned.

• Product Launches:

• Introduction of a no-code Study Designer to facilitate complex ePRO/eCOA studies in just 6-8 weeks.

• Feature Highlights:

• Launched new features to assist in pediatric studies with multi-user accounts.

• Emphasis on crafting a unified digital patient experience.

In summary, Curebase continues to evolve its platform to support faster launches and higher quality clinical trials, demonstrating strong engagement with both technological and participant-centric innovations.